• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of cmajCMAJ Information for AuthorsCMAJ Home Page
CMAJ. Oct 15, 1996; 155(8): 1113–1133.
PMCID: PMC1335371

Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.

Abstract

OBJECTIVE: To recommend clinical practice guidelines for the assessment of people at risk for osteoporosis, and for effective diagnosis and management of the condition. OPTIONS: Screening and diagnostic methods: risk-factor assessment, clinical evaluation, measurement of bone mineral density, laboratory investigations. Prophylactic and corrective therapies: calcium and vitamin D nutritional supplementation, physical activity and fall-avoidance techniques, ovarian hormone therapy, bisphosphonate drugs, other drug therapies. Pain-management medications and techniques. OUTCOMES: Prevention of loss of bone mineral density and fracture; increased bone mass; and improved quality of life. EVIDENCE: Epidemiologic and clinical studies and reports were examined, with emphasis on recent randomized controlled trials. Clinical practice in Canada and elsewhere was surveyed. Availability of treatment products and diagnostic equipment in Canada was considered. VALUES: Cost-effective methods and products that can be adopted across Canada were considered. A high value was given to accurate assessment of fracture risk and osteoporosis, and to increasing bone mineral density, reducing fractures and fracture risk and minimizing side effects of diagnosis and treatment. BENEFITS, HARMS AND COSTS: Proper diagnosis and management of osteoporosis minimize injury and disability, improve quality of life for patients and reduce costs to society. Rationally targeted methods of screening and diagnosis are safe and cost effective. Harmful side effects and costs of recommended therapies are minimal compared with the harms and costs of untreated osteoporosis. Alternative therapies provide a range of choices for physicians and patients. RECOMMENDATIONS: Population sets at high risk should be identified and then the diagnosis confirmed through bone densitometry. Dual-energy x-ray absorptiometry is the preferred measurement technique. Radiography can be adjunct when indicated. Calcium and vitamin D nutritional supplementation should be at currently recommended levels. Patients should be counselled in fall-avoidance techniques and exercises. Immobilization should be avoided. Guidelines for management of acute pain are listed. Ovarian hormone therapy is the therapy of choice for osteoporosis prevention and treatment in postmenopausal women. Bisphosphonates are an alternative therapy for women with established osteoporosis who cannot or prefer not to take ovarian hormone therapy.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (6.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Melton LJ, 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res. 1992 Sep;7(9):1005–1010. [PubMed]
  • Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985;7:178–208. [PubMed]
  • Sernbo I, Johnell O. Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int. 1993 May;3(3):148–153. [PubMed]
  • Ray WA, Griffin MR, Baugh DK. Mortality following hip fracture before and after implementation of the prospective payment system. Arch Intern Med. 1990 Oct;150(10):2109–2114. [PubMed]
  • White BL, Fisher WD, Laurin CA. Rate of mortality for elderly patients after fracture of the hip in the 1980's. J Bone Joint Surg Am. 1987 Dec;69(9):1335–1340. [PubMed]
  • Melton LJ, 3rd, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989 May;129(5):1000–1011. [PubMed]
  • Kanis JA, McCloskey EV. Epidemiology of vertebral osteoporosis. Bone. 1992;13 (Suppl 2):S1–10. [PubMed]
  • Cooper C. Osteoporosis--an epidemiological perspective: a review. J R Soc Med. 1989 Dec;82(12):753–757. [PMC free article] [PubMed]
  • Obrant KJ, Bengnér U, Johnell O, Nilsson BE, Sernbo I. Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations? Calcif Tissue Int. 1989 Mar;44(3):157–167. [PubMed]
  • Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB. Bone gain in young adult women. JAMA. 1992 Nov 4;268(17):2403–2408. [PubMed]
  • Matkovic V, Fontana D, Tominac C, Goel P, Chesnut CH., 3rd Factors that influence peak bone mass formation: a study of calcium balance and the inheritance of bone mass in adolescent females. Am J Clin Nutr. 1990 Nov;52(5):878–888. [PubMed]
  • Kelly PJ, Eisman JA, Sambrook PN. Interaction of genetic and environmental influences on peak bone density. Osteoporos Int. 1990 Oct;1(1):56–60. [PubMed]
  • Riggs BL, Melton LJ., 3rd Involutional osteoporosis. N Engl J Med. 1986 Jun 26;314(26):1676–1686. [PubMed]
  • Riggs BL, Melton LJ., 3rd The prevention and treatment of osteoporosis. N Engl J Med. 1992 Aug 27;327(9):620–627. [PubMed]
  • Cann CE, Genant HK, Ettinger B, Gordan GS. Spinal mineral loss in oophorectomized women. Determination by quantitative computed tomography. JAMA. 1980 Nov 7;244(18):2056–2059. [PubMed]
  • Genant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 1982 Nov;97(5):699–705. [PubMed]
  • Davies MC, Hall ML, Jacobs HS. Bone mineral loss in young women with amenorrhoea. BMJ. 1990 Oct 6;301(6755):790–793. [PMC free article] [PubMed]
  • Prior JC, Vigna YM, Schechter MT, Burgess AE. Spinal bone loss and ovulatory disturbances. N Engl J Med. 1990 Nov 1;323(18):1221–1227. [PubMed]
  • Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990 Mar 1;112(5):352–364. [PubMed]
  • Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995 Mar 23;332(12):767–773. [PubMed]
  • Seeman E, Hopper JL, Bach LA, Cooper ME, Parkinson E, McKay J, Jerums G. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med. 1989 Mar 2;320(9):554–558. [PubMed]
  • Orwoll ES, Bauer DC, Vogt TM, Fox KM. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1996 Jan 15;124(2):187–196. [PubMed]
  • Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer. 1990 Feb;61(2):308–310. [PMC free article] [PubMed]
  • Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF., Jr Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 1987 Mar;106(3):354–361. [PubMed]
  • Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1986 Jun;104(6):777–782. [PubMed]
  • Bauer DC, Browner WS, Cauley JA, Orwoll ES, Scott JC, Black DM, Tao JL, Cummings SR. Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1993 May 1;118(9):657–665. [PubMed]
  • Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983 Aug 4;309(5):265–268. [PubMed]
  • Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BB. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab. 1984 Jun;58(6):1003–1009. [PubMed]
  • Cumming RG, Miller JP, Kelsey JL, Davis P, Arfken CL, Birge SJ, Peck WA. Medications and multiple falls in elderly people: the St Louis OASIS study. Age Ageing. 1991 Nov;20(6):455–461. [PubMed]
  • Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991 Jun 1;114(11):919–923. [PubMed]
  • Long RG, Meinhard E, Skinner RK, Varghese Z, Wills MR, Sherlock S. Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease. Gut. 1978 Feb;19(2):85–90. [PMC free article] [PubMed]
  • Mellström D, Johansson C, Johnell O, Lindstedt G, Lundberg PA, Obrant K, Schön IM, Toss G, Ytterberg BO. Osteoporosis, metabolic aberrations, and increased risk for vertebral fractures after partial gastrectomy. Calcif Tissue Int. 1993 Dec;53(6):370–377. [PubMed]
  • Yendt ER, Cohanim M, Jarzylo S, Jones G, Rosenberg G. Reduced creatinine clearance in primary osteoporosis in women. J Bone Miner Res. 1993 Sep;8(9):1045–1052. [PubMed]
  • Dauphine RT, Riggs BL, Scholz DA. Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med. 1975 Sep;83(3):365–367. [PubMed]
  • Földes J, Tarján G, Szathmari M, Varga F, Krasznai I, Horvath C. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin Endocrinol (Oxf) 1993 Nov;39(5):521–527. [PubMed]
  • Fraser SA, Anderson JB, Smith DA, Wilson GM. Osteoporosis and fractures following thyrotoxicosis. Lancet. 1971 May 15;1(7707):981–983. [PubMed]
  • Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf) 1992 Mar;36(3):229–234. [PubMed]
  • Heaney RP, Gallagher JC, Johnston CC, Neer R, Parfitt AM, Whedon GD. Calcium nutrition and bone health in the elderly. Am J Clin Nutr. 1982 Nov;36(5 Suppl):986–1013. [PubMed]
  • Aloia JF, Cohn SH, Ostuni JA, Cane R, Ellis K. Prevention of involutional bone loss by exercise. Ann Intern Med. 1978 Sep;89(3):356–358. [PubMed]
  • Diamond T, Stiel D, Lunzer M, Wilkinson M, Posen S. Ethanol reduces bone formation and may cause osteoporosis. Am J Med. 1989 Mar;86(3):282–288. [PubMed]
  • Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med. 1995 Feb 27;98(2A):24S–28S. [PubMed]
  • Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, Mascioli SR, Scott JC, Seeley DG, Steiger P, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA. 1990 Feb 2;263(5):665–668. [PubMed]
  • Steiger P, Cummings SR, Black DM, Spencer NE, Genant HK. Age-related decrements in bone mineral density in women over 65. J Bone Miner Res. 1992 Jun;7(6):625–632. [PubMed]
  • Hui SL, Slemenda CW, Johnston CC., Jr Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med. 1989 Sep 1;111(5):355–361. [PubMed]
  • Melton LJ, 3rd, Eddy DM, Johnston CC., Jr Screening for osteoporosis. Ann Intern Med. 1990 Apr 1;112(7):516–528. [PubMed]
  • Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med. 1992 Jun 15;116(12 Pt 1):990–995. [PubMed]
  • Tosteson AN, Rosenthal DI, Melton LJ, 3rd, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med. 1990 Oct 15;113(8):594–603. [PubMed]
  • Ross PD, Davis JW, Vogel JM, Wasnich RD. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int. 1990 Mar;46(3):149–161. [PubMed]
  • Johnston CC, Jr, Slemenda CW. Risk prediction in osteoporosis: a theoretic overview. Am J Med. 1991 Nov 25;91(5B):47S–48S. [PubMed]
  • Bauer DC, Glüer CC, Genant HK, Stone K. Quantitative ultrasound and vertebral fracture in postmenopausal women. Fracture Intervention Trial Research Group. J Bone Miner Res. 1995 Mar;10(3):353–358. [PubMed]
  • Turner CH, Peacock M, Timmerman L, Neal JM, Johnson CC., Jr Calcaneal ultrasonic measurements discriminate hip fracture independently of bone mass. Osteoporos Int. 1995 Mar;5(2):130–135. [PubMed]
  • Heaney RP, Avioli LV, Chesnut CH, 3rd, Lappe J, Recker RR, Brandenburger GH. Osteoporotic bone fragility. Detection by ultrasound transmission velocity. JAMA. 1989 May 26;261(20):2986–2990. [PubMed]
  • Herd RJ, Ramalingham T, Ryan PJ, Fogelman I, Blake GM. Measurements of broadband ultrasonic attenuation in the calcaneus in premenopausal and postmenopausal women. Osteoporos Int. 1992 Sep;2(5):247–251. [PubMed]
  • Ross P, Huang C, Davis J, Imose K, Yates J, Vogel J, Wasnich R. Predicting vertebral deformity using bone densitometry at various skeletal sites and calcaneus ultrasound. Bone. 1995 Mar;16(3):325–332. [PubMed]
  • Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993 Jan 9;341(8837):72–75. [PubMed]
  • Nevitt MC, Johnell O, Black DM, Ensrud K, Genant HK, Cummings SR. Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group. Osteoporos Int. 1994 Nov;4(6):325–331. [PubMed]
  • von der Recke P, Hansen MA, Overgaard K, Christiansen C. The impact of degenerative conditions in the spine on bone mineral density and fracture risk prediction. Osteoporos Int. 1996;6(1):43–49. [PubMed]
  • Hurxthal LM, Vose GP, Dotter WE. Densitometric and visual observations of spinal radiographs. Geriatrics. 1969 May;24(5):93–106. [PubMed]
  • Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988 Dec 29;319(26):1701–1707. [PubMed]
  • Blake AJ, Morgan K, Bendall MJ, Dallosso H, Ebrahim SB, Arie TH, Fentem PH, Bassey EJ. Falls by elderly people at home: prevalence and associated factors. Age Ageing. 1988 Nov;17(6):365–372. [PubMed]
  • Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991 Feb;39(2):142–148. [PubMed]
  • Sattin RW. Falls among older persons: a public health perspective. Annu Rev Public Health. 1992;13:489–508. [PubMed]
  • Province MA, Hadley EC, Hornbrook MC, Lipsitz LA, Miller JP, Mulrow CD, Ory MG, Sattin RW, Tinetti ME, Wolf SL. The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT Trials. Frailty and Injuries: Cooperative Studies of Intervention Techniques. JAMA. 1995 May 3;273(17):1341–1347. [PubMed]
  • Hypothyroidism and enlarging thyroid mass in a young woman. Am J Med. 1993 Nov;95(5):534–541. [PubMed]
  • Dawson-Hughes B. Calcium supplementation and bone loss: a review of controlled clinical trials. Am J Clin Nutr. 1991 Jul;54(1 Suppl):274S–280S. [PubMed]
  • Dalsky GP, Stocke KS, Ehsani AA, Slatopolsky E, Lee WC, Birge SJ., Jr Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med. 1988 Jun;108(6):824–828. [PubMed]
  • Rubin CT, Lanyon LE. Regulation of bone formation by applied dynamic loads. J Bone Joint Surg Am. 1984 Mar;66(3):397–402. [PubMed]
  • Wolf SL, Kutner NG, Green RC, McNeely E. The Atlanta FICSIT study: two exercise interventions to reduce frailty in elders. J Am Geriatr Soc. 1993 Mar;41(3):329–332. [PubMed]
  • Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med. 1990 Sep 27;323(13):878–883. [PubMed]
  • Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992 Dec 3;327(23):1637–1642. [PubMed]
  • Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988 Aug;67(2):373–378. [PubMed]
  • Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab. 1987 Jun;64(6):1165–1168. [PubMed]
  • Gloth FM, 3rd, Tobin JD, Sherman SS, Hollis BW. Is the recommended daily allowance for vitamin D too low for the homebound elderly? J Am Geriatr Soc. 1991 Feb;39(2):137–141. [PubMed]
  • Heaney RP. Thinking straight about calcium. N Engl J Med. 1993 Feb 18;328(7):503–505. [PubMed]
  • Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol. 1979 Mar;53(3):277–281. [PubMed]
  • Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976 May 15;1(7968):1038–1041. [PubMed]
  • Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980 Nov 29;2(8205):1151–1154. [PubMed]
  • Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985 Mar;102(3):319–324. [PubMed]
  • Christiansen C, Christensen MS, Larsen NE, Transbøl IB. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. J Clin Endocrinol Metab. 1982 Dec;55(6):1124–1130. [PubMed]
  • Horsman A, Gallagher JC, Simpson M, Nordin BE. Prospective trial of oestrogen and calcium in postmenopausal women. Br Med J. 1977 Sep 24;2(6090):789–792. [PMC free article] [PubMed]
  • Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med. 1983 Dec 8;309(23):1405–1407. [PubMed]
  • Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med. 1981 Jul;95(1):28–31. [PubMed]
  • Kreiger N, Kelsey JL, Holford TR, O'Connor T. An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol. 1982 Jul;116(1):141–148. [PubMed]
  • Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985 Oct 24;313(17):1044–1049. [PubMed]
  • Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988 Aug;159(2):312–317. [PubMed]
  • Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 1993 Apr 15;328(15):1069–1075. [PubMed]
  • Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990 May;81(5):1680–1687. [PubMed]
  • Kelsey JL, Berkowitz GS. Breast cancer epidemiology. Cancer Res. 1988 Oct 15;48(20):5615–5623. [PubMed]
  • Kaufman DW, Miller DR, Rosenberg L, Helmrich SP, Stolley P, Schottenfeld D, Shapiro S. Noncontraceptive estrogen use and the risk of breast cancer. JAMA. 1984 Jul 6;252(1):63–67. [PubMed]
  • Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989 Aug 3;321(5):293–297. [PubMed]
  • Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA. 1990 Nov 28;264(20):2648–2653. [PubMed]
  • Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 1991 Jan;151(1):67–72. [PubMed]
  • Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991 Apr 17;265(15):1985–1990. [PubMed]
  • Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992 Dec 15;117(12):1016–1037. [PubMed]
  • Whitehead MI, Townsend PT, Pryse-Davies J, Ryder T, Lane G, Siddle NC, King RJ. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med. 1982 Aug;27(8 Suppl):539–548. [PubMed]
  • Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol. 1989 Sep;74(3 Pt 1):398–402. [PubMed]
  • Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol. 1987 Jun;69(6):929–932. [PubMed]
  • Prough SG, Aksel S, Wiebe RH, Shepherd J. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol. 1987 Dec;157(6):1449–1453. [PubMed]
  • Bewtra C, Kable WT, Gallagher JC. Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med. 1988 Feb;33(2):205–208. [PubMed]
  • Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL, Jr, Knapp RC, Stolley PD, Schottenfeld D. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med. 1985 Oct 17;313(16):969–972. [PubMed]
  • Gambrell RD, Jr, Bagnell CA, Greenblatt RB. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review. Am J Obstet Gynecol. 1983 Jul 15;146(6):696–707. [PubMed]
  • Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989 Jan 21;298(6667):147–151. [PMC free article] [PubMed]
  • Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Maffei S, Piaggesi L, Fruzzetti F, Fioretti P. Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas. 1994 Aug;19(2):125–131. [PubMed]
  • Lindsay R, Tohme J, Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women. Contraception. 1986 Oct;34(4):333–340. [PubMed]
  • Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet. 1990 Aug 4;336(8710):265–269. [PubMed]
  • Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 1984 Jun;63(6):759–763. [PubMed]
  • Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1995 Jan 1;122(1):9–16. [PubMed]
  • el-Hajj Fuleihan G, Brown EM, Curtis K, Berger MJ, Berger BM, Gleason R, LeBoff MS. Effect of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism. Arch Intern Med. 1992 Sep;152(9):1904–1909. [PubMed]
  • Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988 Jan 23;1(8578):143–146. [PubMed]
  • Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol. 1994 Oct;21(10):1922–1926. [PubMed]
  • Skingle SJ, Crisp AJ. Increased bone density in patients on steroids with etidronate. Lancet. 1994 Aug 20;344(8921):543–544. [PubMed]
  • Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med. 1995 May;98(5):459–463. [PubMed]
  • Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. [PubMed]
  • Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, 3rd, Yanover MJ, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990 Jul 12;323(2):73–79. [PubMed]
  • Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH., 3rd Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993 Dec;95(6):557–567. [PubMed]
  • Chesnut CH, 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995 Aug;99(2):144–152. [PubMed]
  • Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 Nov 30;333(22):1437–1443. [PubMed]
  • Giannini S, D'Angelo A, Malvasi L, Castrignano R, Pati T, Tronca R, Liberto L, Nobile M, Crepaldi G. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 1993 Mar-Apr;14(2):137–141. [PubMed]
  • Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989 Dec 23;2(8678-8679):1469–1471. [PubMed]
  • Kanis JA, McCloskey EV, Sirtori P, Khan S, Fern D, Eyres K, Aaron J, Beneton MN. Rationale for the use of clodronate in osteoporosis. Osteoporos Int. 1993;3 (Suppl 2):S23–S28. [PubMed]
  • Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 1989 Apr;30(4):435–442. [PubMed]
  • Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992 Sep 5;305(6853):556–561. [PMC free article] [PubMed]
  • Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, Gaucher A, Prost A, Zeigler G, Netter P. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet. 1988 Aug 13;2(8607):361–365. [PubMed]
  • Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med. 1995 Sep 15;123(6):401–408. [PubMed]
  • Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 1990 Nov 1;113(9):649–655. [PubMed]
  • Ott SM, Chesnut CH., 3rd Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989 Feb 15;110(4):267–274. [PubMed]
  • Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992 Feb 6;326(6):357–362. [PubMed]
  • Whitehead MI, Townsend PT, Pryse-Davies J, Ryder T, Lane G, Siddle NC, King RJ. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med. 1982 Aug;27(8 Suppl):539–548. [PubMed]
  • Gambrell RD, Jr, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol. 1980 Jun;55(6):732–738. [PubMed]

Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

Formats:

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...